Review
doi: 10.1007/s10928-005-5910-2.
Modelling and simulation in the development and use of anti-cancer agents: an underused tool?
Affiliations
- PMID: 16222783
- DOI: 10.1007/s10928-005-5910-2
Item in Clipboard
Review
Modelling and simulation in the development and use of anti-cancer agents: an underused tool?
J Pharmacokinet Pharmacodyn.
2004 Dec.
Abstract
To help identify the role of modelling and simulation in the development of anti-cancer agents, their main advantages and the obstacles to their rational use, an expert meeting was organized by COST B15. This manuscript presents a synthesis of views expressed at that meeting and indicates future directions. The manuscript also shows some examples where modelling and simulation have proven to be of relevant value in the drug development process for anti-cancer agents.
Similar articles
-
The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.Cancer Invest. 2002;20 Suppl 2:38-44. doi: 10.1081/cnv-120014885. Cancer Invest. 2002. PMID: 12442348 Review. No abstract available.
-
Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.Clin Breast Cancer. 2004 Oct;5(4):273-8. doi: 10.3816/cbc.2004.n.030. Clin Breast Cancer. 2004. PMID: 15507172 Clinical Trial.
-
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.Oncologist. 2003;8(3):232-40. doi: 10.1634/theoncologist.8-3-232. Oncologist. 2003. PMID: 12773745 Clinical Trial.
-
Rational development of capecitabine.Semin Oncol. 2000 Oct;27(5 Suppl 10):144-8. Semin Oncol. 2000. PMID: 11049047 Review. No abstract available.
-
Capecitabine and docetaxel combination for the treatment of breast cancer.Womens Health (Lond). 2008 Jan;4:11-22. doi: 10.2217/17455057.4.1.11. Womens Health (Lond). 2008. PMID: 19072447 Review.
Cited by
-
Semi-mechanistic model for neutropenia after high dose of chemotherapy in breast cancer patients.Pharm Res. 2009 Aug;26(8):1952-62. doi: 10.1007/s11095-009-9910-6. Epub 2009 Jun 2. Pharm Res. 2009. PMID: 19488837
-
Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.Clin Pharmacokinet. 2016 Aug;55(8):1015-25. doi: 10.1007/s40262-016-0374-7. Clin Pharmacokinet. 2016. PMID: 26946136 Clinical Trial.
-
Optimal chemotherapy for leukemia: a model-based strategy for individualized treatment.PLoS One. 2014 Oct 13;9(10):e109623. doi: 10.1371/journal.pone.0109623. eCollection 2014. PLoS One. 2014. PMID: 25310465 Free PMC article.
-
Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.Clin Pharmacokinet. 2009;48(7):477-87. doi: 10.2165/11313400-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19691369
-
Modeling NSCLC progression: recent advances and opportunities available.AAPS J. 2013 Apr;15(2):542-50. doi: 10.1208/s12248-013-9461-y. Epub 2013 Feb 13. AAPS J. 2013. PMID: 23404126 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources